Details for Patent: 7,268,109

Title:	Method for reducing pain
Abstract:	The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the .omega.-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
Inventor(s):	Ellis; David J. (Los Altos, CA), Miljanich; George P. (Redwood City, CA), Shields; David E. (San Lorenzo, CA)
Assignee:	Elan Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:	Oct 01, 2004
Application Number:	10/956,252
Claims:	1. A pharmaceutical formulation comprising ziconotide, an antioxidant, and morphine, wherein the concentration of ziconotide is 10-25 .mu.g/ml and the concentration of morphine is 7.5-18.75 mg/ml, wherein ziconotide retains its potency and is physically and chemically compatible with morphine. 2. The pharmaceutical formulation according to claim 1, wherein said antioxidant is methionine. 3. The pharmaceutical formulation according to claim 1, which has pH between 4 to 4.5. 4. The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is suitable for intrathecal administration. 5. The pharmaceutical formulation according to claim 4, wherein the pharmaceutical formulation is suitable for continuous intrathecal infusion. 6. The pharmaceutical formulation according to claim 1, wherein said formulation is stable in a drug dispensing implantable pump at 37.degree. C. for at least 7 days.